RPTX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.420

-37.31%

-0.290

-59.15%

-0.160

-58.97%

Estimates Revision

The market is revising Downward the revenue expectations for Repare Therapeutics Inc. (RPTX) for FY2025, with the revenue forecasts being adjusted by -10.35% over the past three months. During the same period, the stock price has changed by 41.11%.

Revenue Estimates for FY2025

Revise Downward

-10.35%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+19.89%

In Past 3 Month

Stock Price

Go Up

+41.11%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

TD Cowen

Marc Frahm

Buy

Hold

downgrade

$1.82

2025-11-17

Reason

TD Cowen

Marc Frahm

Price Target

$1.82

2025-11-17

downgrade

Buy

Hold

Reason

TD Cowen analyst Marc Frahm downgraded Repare Therapeutics to Hold from Buy after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.

H.C. Wainwright

Buy

downgrade

$5 -> $3

2025-10-27

Reason

H.C. Wainwright

Price Target

$5 -> $3

2025-10-27

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Repare Therapeutics to $3 from $5 and keeps a Buy rating on the shares. The firm says the initial RP-1664 data "raises questions over its viability." As such, the firm removed risk-adjusted revenue forecasts for the agent.

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$10 → $5

2025-03-07

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10 → $5

2025-03-07

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Repare Therapeutics Inc (RPTX.O) is -2.69, compared to its 5-year average forward P/E of -5.24. For a more detailed relative valuation and DCF analysis to assess Repare Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.24

Current PE

-2.69

Overvalued PE

0.35

Undervalued PE

-10.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.61

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.23

Undervalued EV/EBITDA

-6.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

62.46

Current PS

11.08

Overvalued PS

179.03

Undervalued PS

-54.10

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RPTX News & Events

Events Timeline

No data

News

7.5

2025-12-26NASDAQ.COM

Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway

2.0

2025-12-24NASDAQ.COM

Repare Therapeutics Surges 18.9% Leading Biotechnology Sector Gains

8.5

2025-12-24NASDAQ.COM

Repare Therapeutics Acquires Gilead's RP-3467 for Up to $30 Million

People Also Watch

Frequently Asked Questions

What is Repare Therapeutics Inc (RPTX) stock price today?

The current price of RPTX is 2.54 USD — it has increased 0.4 % in the last trading day.

What is Repare Therapeutics Inc (RPTX)'s business?

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

What is the price predicton of RPTX Stock?

What is Repare Therapeutics Inc (RPTX)'s revenue for the last quarter?

Repare Therapeutics Inc revenue for the last quarter amounts to 11.62M USD, decreased % YoY.

What is Repare Therapeutics Inc (RPTX)'s earnings per share (EPS) for the last quarter?

Repare Therapeutics Inc. EPS for the last quarter amounts to 0.08 USD, decreased -109.88 % YoY.

What changes have occurred in the market's expectations for Repare Therapeutics Inc (RPTX)'s fundamentals?

How many employees does Repare Therapeutics Inc (RPTX). have?

Repare Therapeutics Inc (RPTX) has 129 emplpoyees as of January 10 2026.

What is Repare Therapeutics Inc (RPTX) market cap?

Today RPTX has the market capitalization of 109.50M USD.